FY2027 EPS Forecast for Pharming Group Lowered by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – HC Wainwright cut their FY2027 earnings per share estimates for shares of Pharming Group in a report issued on Monday, September 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.50 per share for the year, down from their prior forecast of $0.60. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

PHAR has been the subject of several other research reports. Canaccord Genuity Group increased their price objective on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $38.67.

Pharming Group Stock Down 2.5%

PHAR opened at $10.55 on Wednesday. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. Pharming Group has a 12 month low of $9.62 and a 12 month high of $21.34. The business’s 50-day moving average price is $11.92 and its 200-day moving average price is $13.75. The company has a market cap of $746.73 million, a P/E ratio of 87.92 and a beta of 0.01.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.